Lannett Says Areva Reneged On Cancer-Drug Deal After Ch. 11

By Dorothy Atkins · August 29, 2024, 9:35 PM EDT

Lannett Pharmaceuticals hit generic-drug maker Areva Pharmaceuticals with a contract suit in Delaware's Court of Chancery on Thursday, accusing Areva of breaching their 2022 agreement that gave Lannett exclusive rights to...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login